Market Overview

Eli Lilly Reports Phase 3 Results of Solanezumab; Decline in Expedition1 Study Not Significant

Share:
Related LLY
5 'Key Pipeline Catalysts' To Watch At Eli Lilly
After A Blockbuster 2014, What Will 2015 Hold For Pharmaceutical M&A?
FDA imposes limits on testosterone drugs and labeling changes to warn of potential heart risks (Seeking Alpha)

Eli Lilly and Company (NYSE: LLY) today announced its detailed results for the Phase 3, double-blind, placebo-controlled EXPEDITION studies in patients with mild-to-moderate Alzheimer's disease. This announcement follows the presentation of results from independent analyses of the EXPEDITION study data conducted by the Alzheimer's Disease Cooperative Study (ADCS), an academic research consortium, at the annual meeting of the American Neurological Association (ANA) by Rachelle Doody, M.D., Ph.D., professor of Neurology and the Effie Marie Cain Chair in Alzheimer's Disease Research, Baylor College of Medicine. Dr. Doody is a member of the steering committee for the ADCS.

Posted-In: News FDA

 

Related Articles (LLY)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→